Pharming (PHAR) Net Income towards Common Stockholders (2020 - 2026)

Pharming (PHAR) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$10.3 million in Q2 2026.

• Quarterly Net Income towards Common Stockholders fell 3.12% year-over-year to -$10.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$39.9 million (down 60.26% YoY) and the FY2025 annual result came in at $2.9 million, up 124.08% from the prior year.
• Net Income towards Common Stockholders rose to -$10.3 million in Q2 2026, from -$14.9 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $28.3 million in Q4 2022 to a low of -$14.9 million in Q1 2025.
• A 5-year average of -$2.4 million and a median of -$11.05 in 2024 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders jumped 151.11% — and 2025, when it tumbled 1336363536.36%.
• Tracing PHAR's Net Income towards Common Stockholders over 5 years: stood at $28.3 million in 2022, then tumbled by 100.0% to -$7.4 in 2023, then sank by 98.65% to -$14.7 in 2024, then jumped by 136.05% to $5.3 in 2025, then sank by 195056703.77% to -$10.3 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$10.3 million (Q2 2026), -$14.9 million (Q1 2026), and $5.3 (Q4 2025), per Business Quant data.